Decision: Favourable

Decisions Table

Study Title:

A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients with Relapsed Refractory Multiple Myeloma

  • NREC Code:

    22-NREC-CT-109

  • Decision:

    Favourable

  • Meeting Date:

    22/06/2022

  • Study Type:

    CT application

  • Principal Investigator:

    Dr Kamal Fadalla

  • PI Institution:

    St Vincent's University Hospital

  • Sponsor:

    Takeda Development Center Americas, Inc.

Scroll to Top